×
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
NASDAQ:CDXS

Codexis Stock Forecast, Price & News

$12.00
+1.12 (+10.29%)
(As of 07/5/2022 05:45 PM ET)
Add
Compare
Today's Range
$10.55
$12.02
50-Day Range
$8.35
$12.82
52-Week Range
$8.11
$42.01
Volume
634,321 shs
Average Volume
746,541 shs
Market Capitalization
$783.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.25

Codexis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
193.8% Upside
$35.25 Price Target
Short Interest
Healthy
8.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.67
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$396,935 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.41) to ($0.36) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.72 out of 5 stars

Medical Sector

666th out of 1,426 stocks

Industrial Organic Chemicals Industry

15th out of 25 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

Codexis logo

About Codexis (NASDAQ:CDXS) Stock

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CDXS Stock News Headlines

The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Codexis (NASDAQ:CDXS) Stock Price Up 8.4%
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022
If you missed the boat on Tesla stocks, it's not too late! But don't follow the crowd and think EV makers are the most exciting investment. The smart money is focused on the miners that supply battery-grade lithium to EV manufacturers. With lithium demand expected to increase 10x by 2030, this industry is set to explode...
Codexis (NASDAQ:CDXS) Sets New 12-Month Low at $8.68
See More Headlines

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CDXS
CUSIP
19200510
Employees
261
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
7/06/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$35.25
High Stock Price Forecast
$39.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+193.8%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-21,280,000.00
Pretax Margin
-16.69%

Debt

Sales & Book Value

Annual Sales
$104.75 million
Book Value
$2.53 per share

Miscellaneous

Free Float
60,733,000
Market Cap
$783.60 million
Optionable
Optionable
Beta
1.90














Codexis Frequently Asked Questions

Should I buy or sell Codexis stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Codexis stock.
View analyst ratings for Codexis
or view top-rated stocks.

What is Codexis' stock price forecast for 2022?

4 brokerages have issued 12-month price objectives for Codexis' stock. Their CDXS stock forecasts range from $30.00 to $39.00. On average, they anticipate Codexis' stock price to reach $35.25 in the next year. This suggests a possible upside of 193.8% from the stock's current price.
View analysts' price targets for Codexis
or view top-rated stocks among Wall Street analysts.

How has Codexis' stock performed in 2022?

Codexis' stock was trading at $31.27 at the beginning of the year. Since then, CDXS shares have decreased by 61.6% and is now trading at $12.00.
View the best growth stocks for 2022 here
.

When is Codexis' next earnings date?

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Codexis
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. The biotechnology company had revenue of $35.34 million for the quarter, compared to analysts' expectations of $28.58 million. Codexis had a negative trailing twelve-month return on equity of 12.56% and a negative net margin of 16.85%. The business's revenue for the quarter was up 96.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.14) earnings per share.
View Codexis' earnings history
.

What guidance has Codexis issued on next quarter's earnings?

Codexis issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $152.00 million-$158.00 million, compared to the consensus revenue estimate of $155.49 million.

Who are Codexis' key executives?

Codexis' management team includes the following people:
  • Mr. John J. Nicols, Pres, CEO & Director (Age 58, Pay $1.33M) (LinkedIn Profile)
  • Mr. Ross Taylor Jr., M.B.A., Sr. VP & CFO (Age 59, Pay $667.31k)
  • Dr. Karl A. Schoene Ph.D., Sr. VP of Devel. & Operations
  • Ms. Asli Aras Ph.D., VP of Corp. Devel.
  • Ms. Karen Frechou-Armijo, Sr. VP & Head of HR
  • Dr. Gjalt Huisman Ph.D., Sr. VP of Strategic Devel. & GM of Biotherapeutics
  • Mr. Rob Wilson Ph.D., Sr. VP & GM of Performance Enzymes
  • Dr. Stefan Lutz Ph.D., Sr. VP of Research
  • Mr. Robert Sato M.B.A., Ph.D., Sr. VP of Pharmaceutical Devel., Quality & Regulatory
  • Prof. Gerhard N. Mayr, Special Advisor to the Board (Age 76)

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis CEO John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among Codexis' employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $12.00.

How much money does Codexis make?

Codexis (NASDAQ:CDXS) has a market capitalization of $783.60 million and generates $104.75 million in revenue each year. The biotechnology company earns $-21,280,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does Codexis have?

Codexis employs 261 workers across the globe.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for Codexis is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.

This page (NASDAQ:CDXS) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.